The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: Is allosteric functional selectivity a valuable therapeutic property?

Molecular Pharmacology

Volumn 75, Issue 3, 2009, Pages 490-501

  Muniz Medina, Vanessa M ^a   Jones, Stacey ^a   Maglich, Jodi M ^a   Galardi, Cristin ^a   Hollingsworth, Robert E ^a   Kazmierski, Wieslaw M ^a   Ferris, Robert G ^a   Edelstein, Mark P ^a   Chiswell, Karen E ^a   Kenakin, Terry P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 8 [4 (2 BUTOXYETHOXY)PHENYL] 1,2,3,4 TETRAHYDRO 1 ISOBUTYL N [4 (1 PROPYL 1H IMIDAZOL 5 YLMETHYLSULFINYL)PHENYL] 1 BENZAZOCINE 5 CARBOXAMIDE; APLAVIROC; CHEMOKINE RECEPTOR CCR5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; VICRIVIROC; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTERNALIZATION; OSTEOSARCOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ENTRY; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MONONUCLEAR CELL; PATHOGENICITY; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

ALLOSTERIC REGULATION; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

EID: 62149094752     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.052555     Document Type: Article

References (68)

1. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, and Berger EA (1996) CC CCR5, a RANTES, MIP-lα, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1.Science 272:1955-1958.
2. Alkhatib G, Locati M, Kennedy PE, Murphy PM, and Berger EA (1997) HIV-1 coreceptor activity of CCR5 and Its inhibition by chemokines: independence from G protein signaling and importance of coreceptor dowimiodulation. Virology 234:340-348.
3. Amara A. Gall SL, Schwartz O, Salamero J, Montes M, Loetscher P, Baggiolini M, Virelizier JL, and Arenzana-Seisdedos F (1997) HIV Coreceptor downregulation as antiviral principle: SDF-1 α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 186:139-146.
4. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, et al. (1999) A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 96:5698-5703.
5. Baba M, Takashima K, Miyake H, Kanzaki N, Teshima K, Wang X, Shiraishi M, and Iizawa Y (2005) TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infecton in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 49:4584-4591.
6. Baroudy BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Smith EM, Steensma R, et al. (2000a), inventors; Schering Corp., Baroudy BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Smith EM, Steensma R, et al., assignees. Piperazine derivatives useful as CCR5 antagonists. World Patent no. WO2000066558. 2000 Sep 11.
7. Baroudy BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Steensma R, Tagat JR, et al. (2000b), inventors; Schering Corp., Baroudy BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Steensma R, Tagat JR, et al., assignees. Piperidine derivatives useful as CCR5 antagonists. World Patent no. WO2000066559. 2000 Sep 11.
8. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, Bochner BS, and Schleimer RP (1997) Cutaneous injection of RANTES causes eosinophil recruitment: comparison of nonallergic and allergic human subjects. J Immunol 159: 2962-2972.
9. Black JW and Leff P (1983) Operational models of pharmacological agonist. Proc R Soc Lond B Biol Sci 220:141-162.
10. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, Daugherty BL, Fhike PE, Hale JJ, Lynch CL, et al. (2003) Binding of 2-aryl-4-(piperidinl-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket. Biochemistry 42: 1544-1550.
11. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, et al. (1996) The β- chemokinereceptors CCR3 and CCR5 facillitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
12. Christopoulos A and Kenakin T (2002) G-protein coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
13. Crabb C (2006) GlaxoSmithKline ends aplaviroc trials. AIDS 20:641.
14. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study [published erratum appears in Science 274:1069, 1997]. Science 273:1856-1862.
15. Demarest JS, Shibayama R, Ferris C, Vavro M, St Clair M, and Boone M (2004) A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity. XV International AIDS Conference; Bangkok, Thailand; 2004 July 11-16. Abstract WeOrAl231.
16. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. (1996) Identification of a major coreceptor for primary isolates of HIV-1. Nature 381:661-666.
17. de Silva E and Stumpf MP (2004) HIV and the CCR5-A32 resistance allele. FEMS Microbiol Lett 241:1-12.
18. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, et al. (1996) HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
19. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, et al. (2000) A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 97:5639-5644.
20. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
21. Eri R, Jonsson JR, Pandeya N, Purdie DM, Clouston AD, Martin N, Duffy D, Powell EE, Fawcett J, Florin TH, et al. (2004) CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun 5:444-450.
22. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman Al, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR antagonist, in patients infected with HIV-1. Nat Med 11:1170-1172.
23. Garzino-Demo A, Moss RB, Margolick JB, Cleghorn F, Sill A, Blattner WA, Cocchi F, Carlo DJ, DeVico AL, and Gallo RC (1999) Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 96:11986-11991.
24. Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, and Murphy PM (2006) CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203:35-40.
25. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G. Nibbs RJ. Freedman BI, Quinones MP, Bamshad MJ, et al. (2005) The influenced CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440.
26. Hartley O, Gaertner H, Wilken J, Thompson D, Fish R, Ramos A, Pastore C, Dufour B, Cerini F, Melotti A, et al. (2004) Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA 101:16460-16465.
27. Hazen R, Harvey R, Ferris R, Craig C, Yates P, Griffin P, Miller J, Kaldor I, Ray J, Samano V, et al. (2007) In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother 51:3147-3154.
28. 1 cycle arrest in T lymphocytes results in increased extracellular levels of β-chemokines: a strategy to inhibit R5 HIV-1. Proc Natl Acad Sci USA 100:4179- 4184.
29. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, et al. (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 2:1240-1243.
30. Jakubik J, Bacáková L, El-Fakahany EE, and Tucek S (1997) Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 52:172-179.
31. Jenkinson S, McCoy D, Kerner S, Ferris R, Lawrence W, Fox T, and Smith C (2003) Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion. Receptors Channels 9:117-123.
32. Kazmierski W, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, and Kenakin TP (2003) Recent progress in discovery of small-molecule CCR5 chemokine receptor ligsnds as HIV-1 inhibitors. Bioorg Med Chem. 11:2663-2676.
33. Kazmierski W, Peekham JP, Duan M, Kenakin TP, Jenkinson S, Gudmmidsson KS, Piscitelli SC, and Feldman PL (2005) Recent progress in the discovery of new CCR5 and CXCR4 chemokine receptor antagonists as inhibitors of HIV-1 entry. Part 2. Curr Med Chem Anti-Infective Agents 4:133-152.
34. Kazmierski W, Gudmundsson KS, and Piscitelli SC (2007) Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development. Annu Rep Med Chem 42:301-320.
35. Kenakin TP (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
36. Kenakin T, Jenkinson S, and Watson C (2006) Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319:710-723.
37. Ketas TJ, Kuhmann SE, Palmer A, Zurita J, He W, Ahuja SK, Klasse PJ, and Moore JP (2007) Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 364:281-290.
38. Kew JN, Trube G, and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effects of ifenprodil in rat cultured cortical neurons. J Physiol 497:761-772.
39. + T cells: role of signal transduction. Proc Nail Acad Sci USA 95:11880-11885.
40. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, and Dioszegi M (2008) Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73:789-800.
41. Lederman MM, Penn-Nicholson A, Cho M, and Mosier D (2006) Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815-826.
42. Lin YL, Mettling C, Portales P, Réant B, Robert-Hebmami V, Reynes J, Clot J, and Corbeau P (2006) The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G[alpha]i-protein signalling. AIDS 20:1369-1377.
43. Mack M, Lackow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215-1224.
44. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78:8654-8662.
45. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y. Ding J, Arnold GF, et al. (2006) Structural and molecular interactions of CCR5 inhibitors with CCR5. J Biol Chem 281:12688-12698.
46. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, Lee B, Doms RW, Margolick J, Buchbinder S, et al. (1998) Genetic variation of AIDS progression by a promoter variant of CCR5. Science 282:1907-1911.
47. McDermott DH, Zimmerman PA, Guignard F, Kleeberger OA, Leitman SF, and Murphy PM (1998) CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 352:866-870.
48. Mitsuya H, Maeda K, Shibayama S, Takaoka Y (2002) inventors; ONO Pharmaceuticals, Mitsuya H, Maeda K, Shibayama S, Takaoka Y, assignees. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient. World Patent no. WO2002074769. 2002 Sep 26.
49. Moench C, Uhrig A, Lohse AW, and Otto G (2004) CC chemokine receptor 5delta32 polymorphism - a risk factor for ischemie-type biliary lesions following orthotopic liver transplantation. Liver Transpl 10:434-439.
50. Nardese V, Longhi R, Polo S, Sironi F, Arcelloni C, Paroni R, DeSantis C, Sarmientos P, Rizzi M, Bolognesi M, et al. (2001) Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES. Nat Struct. Biol 8:611-615.
51. Nishikawa M. Takashima K, Nishi T, Fumta RA, Kanzaki N, Yamamoto Y, and Fujisawa J (2005) Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob Agents Chemother 49:4708-4715.
52. Pastore C, Picchio GR, Galimi F, Fish R, Hartley O, Offord RE, and Mosier DE (2003) Two mechanisms for human immunodeficiency virus type 1 inhibition by n-terminal modifications of RANTES. Antimicrob Agents Chemother 47:509-517.
53. Perros M, Price DA, Stammen BL, and Wood A (2001) inventors; Pfizer, Inc., Perros M, Price DA, Stammen BL, and Wood A, assignees. Preparation of therapeutic tropane derivatives. World Patent no. WO2001090106. 2001 Nov 29.
54. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, Mcintosh L, Goodwin G, Walker G, et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495.
55. Rogez C, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, and Glayette P (2003) Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and β-chemokin.es. J Virol 77:12914-12920.
56. Schols D (2006) HIV co-receptor inhibitors as novel class of anti-HIV drugs. Antivir Res 71:216-226.
57. Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, et al. (2006) Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 349:41-54.
58. Shieh B, Yan YP, Ko NY, Liau YE, Liu YC, Lin HH, Chen PP, and Li C (2001) Detection of elevated serum beta chemokine levels in seronegative Chinese individuals exposed to human immunodeficiency virus type 1. Clin Infect Dis 33:273-279.
59. Shiraishi M, Baba M, Aikawa K, Kanzaki N, Seto M, and Iizawa Y (2003), inventors; Takeda Chemical Industries, Ltd., Shiraishi M, Baba M, Aikawa K, Kanzaki N, Seto M, and Iizawa Y, assignees. Bicyclic compound, production and use as HIV inhibitors. World Patent no. WO2003014105. 2003 Feb 20.
60. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TN, and Proudfoot AE (1997) Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279.
61. Steel RG, Torrie JH, and Dickey DA (1997) Principles and Procedures of Statistics: A Biometrical Approach, 3rd ed, McGraw-Hill, Boston, MA.
62. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmaim S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, et al. (2003) Analysis of the mechanism by which small molecule CCR5 antagonists SCH-3,51,125 and SCH-3,50,581 inhibit human immunodeficiency virus type 1 entry. J Virol 77:5201-5208.
63. Ullum H, Cozzi Lepri A, Victor J, Aladdin H, Phillips AN, Gerstoft J, Skinhøj P, and Pedersen BK (1998) Production of β-ehemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-lβ are associated with a decreased risk of HIV disease progression. J Infect Dis 177:331-336.
64. Watson C, Jenkinson S, Kazmierski W, and Kenakin TP (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 67:1268-1282.
65. Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, Venkatesan S, Farber JM, and Fauci AS (1997) Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389:981-985.
66. Welniak LA, Wang Z, Sun K, Kuziel W, Anver MR, Blazar BR, and Murphy WJ (2004) An absence of CCR5 on donor cells results in acceleration of acute graftvs-host disease. Exp Hematol 32:318-324.
67. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, and Perros M (2007) Reduced maximal inhibition in phenotypic susceptibility studies indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 81:2359-2371.
68. Xiang J, George. SL, Wünschmann S, Chang Q, Klinzman D, and Stapleton JT (2004) Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MlP-lα, MIP-1βand SDF-1. Lancet 363:2040-2046.